In an Oct. 12, 2026 statement, the Coalition for Epidemic Preparedness Innovations (CEPI), which was co-founded by the Bill & Melinda Gates Foundation, has announced that its experimental Bundibugyo Ebola Virus vaccine is advancing toward Phase 2/3 clinical trials.1 The statement comes as an ongoing Bundibugyo ebolavirus outbreak involving a more deadly form of Ebola continues to affect Ituri and other provinces of the Democratic Republic of the Congo (DRC) since May 2026.2
“Final preparations are underway for Tumaini, which means “hope” in Swahili,” the statement reads. “This pivotal Phase 2/3 clinical trial will evaluate the safety, immunogenicity and efficacy of vaccine candidates against Bundibugyo virus (BDBV), including Ervebo which is currently licensed for use to prevent Ebola virus (EBOV). The trial will support the Government-led response to the ongoing ebolavirus outbreak in the DRC. Subject to ethical and regulatory approval, it is expected to begin in the coming weeks.”3
Tumaini is not a vaccine itself, but the name of a Phase 2/3 clinical trial in DRC designed to evaluate multiple experimental vaccines targeting the Bundibugyo Ebola virus, which is a rarer but potentially deadly form of Ebola disease for which no licensed vaccines or approved antiviral treatments exist. Vaccine candidates being developed for potential inclusion in the trial include Moderna’s mRNA-1469, which uses mRNA technology, and the University of Oxford’s ChAdOx1 BDBV, which uses viral-vector technology rather than mRNA.4 5
NVIC co-founder and president Barbara Loe Fisher said in an emailed statement:
Calling an experimental vaccine trial Tumaini, the Swahili word for “hope,” does not establish that the vaccines being tested are safe or effective. Using manipulative language to create a positive impression of the experimental Ebola vaccine takes attention away from the need to produce good scientific evidence pre-licensure, especially when the potential for serious adverse reactions and potential vaccine strain virus transmission remains under investigation.”6
Only Licensed Ebola Vaccine Does Not Target Bundibugyo Virus Responsible for DRC Outbreak; Package Insert Warns of Potential Viral Shedding
The first and only U.S.-licensed Ebola vaccine, developed by Merck and marketed under the brand name Ervebo (rVSVΔG-ZEBOV-GP), was designed to target the Zaire ebolavirus species, the most common Ebola species, but not the Bundibugyo strain driving the ongoing outbreak in the DRC and Uganda.7 Merck’s product information package insert states that Ervebo is “a live recombinant viral vaccine consisting of a vesicular stomatitis virus (VSV) backbone deleted for the VSV envelope glycoprotein and substituted with the envelope glycoprotein of the Zaire ebolavirus (Kikwit 1995 strain). The vaccine virus is grown in serum-free Vero cell cultures.” It also states that each dose “dose may contain residual amounts of host cell DNA.”8
The Ervebo prescribing information additionally notes that transmission of the live vaccine virus is theoretically possible, with vaccine virus RNA detected in bodily fluids following vaccination. As the package insert states: “Transmission of vaccine virus is a theoretical possibility. Vaccine virus RNA has been detected in blood, saliva, or urine for up to 14 days after vaccination. The duration of shedding is not known; however, samples taken 28 days after vaccination tested negative. Vaccine virus RNA has been detected in fluid from skin vesicles that appeared after vaccination.”9
CDC Reports Second-Largest Ebola Outbreak on Record as Cases Reach 9,964, With 4,841 Confirmed Deaths in DRC
The World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC) in May 2026. As of Oct. 25, 2026, the U.S. Centers for Disease Control and Prevention (CDC) reports 9,964 confirmed cases and 4,841 confirmed deaths in the Democratic Republic of the Congo (DRC), making the ongoing Bundibugyo Ebola outbreak the country’s 17th Ebola outbreak and the second-largest Ebola outbreak on record.10
The Vaccine Reaction previously reported that CEPI announced in January 2026 that it had awarded Moderna, Inc. and the University of Oxford a $26.7 million contract to begin developing Bundibugyo ebolavirus (BDBV) mRNA and viral vector vaccine candidates targeting the same virus responsible for the ongoing outbreak in the DRC, with cases also reported in Uganda. The announcement came approximately four months before the WHO’s public health emergency declaration, the WHO’s highest level of global health alert.11 12
Organization Funding Bundibugyo Vaccine Development Also Financing Pivotal Clinical Trial
According to CEPI’s Oct. 23 announcement, the Tumaini Phase 2/3 trial is now underway, with the first participant receiving the licensed Ebola vaccine Ervebo. The first participant received Ervebo on Oct. 23, 2026, in Bunia, DRC, marking the trial’s official start.13
The trial is funded by CEPI’s Bundibugyo virus vaccine development program. CEPI identifies the Institut National de Recherche Biomédicale (INRB) and the University of Antwerp as trial co-sponsors and states that the DRC Ministry of Health provides oversight, while an independent WHO-led process prioritizes vaccine candidates.
However, given CEPI’s financial and institutional interest in the vaccine’s successful development, the statement does not specify the extent of CEPI’s involvement in trial design, data analysis or interpretation of findings; whether an independent data and safety monitoring board has been established; or whether researchers can publish unfavorable results without CEPI’s approval.14
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
Click here to view References:1 Coalition for Epidemic Preparedness Innovations. Final Preparations Underway for Pivotal Phase 2/3 Bundibugyo Vaccine Trial. Oct. 13, 2026.
2 Cáceres M. Ebola Outbreak Pushing Development of Vaccines for Bundibugyo Strain. The Vaccine Reaction May 27, 2026.
3 Ibid.
4 CEPI. Moderna’s Bundibugyo Ebolavirus Vaccine Candidate Enters First Human Trial, Backed by CEPI. Aug. 4, 2026.
5 University of Oxford. First Volunteer Vaccinated in the World’s First Bundibugyo Ebolavirus Vaccine Trial. July 24, 2026.
6 Fisher BL. Personal communication (email to author). Oct. 27, 2026.
7 Merck Sharp & Dohme LLC. Package Insert – Ervebo. U.S. Food and Drug Administration. April 2026.
8 Ibid.
9 Ibid.
10 U.S. Centers for Disease Control and Prevention. Ebola Outbreak: Current Situation. October 2026.
11 Baker A. Ebola Bundibugyo Vaccines in Development Four Months Before Outbreak. The Vaccine Reaction June 2, 2026.
12 World Health Organization. Epidemic of Ebola Disease Caused by Bundibugyo Virus in the Democratic Republic of the Congo and Uganda Determined a Public Health Emergency of International Concern. May 17, 2026.
13 CEPI. First Participant Vaccinated in Pivotal Phase 2/3 Bundibugyo Vaccine Trial in DRC. Oct. 23, 2026.
14 CEPI. Final Preparations Underway for Pivotal Phase 2/3 Bundibugyo Vaccine Trial. Oct. 13, 2026.












